Ian Meredith, currently professor of Medicine and Cardiology for Monash University, Director of MonashHeart and Monash Health and as executive director of the Monash Cardiovascular Research Centre in Melbourne, Australia, is to take over from Keith Dawkins as executive vice president and global chief medical officer in January 2017. He will lead clinical and medical affairs across Boston Scientific and will provide global leadership of the company’s clinical trial strategy.
Meredith has more than 25 years of experience as a clinical and interventional cardiologist. He has performed more than 10,000 invasive cardiac and coronary procedures, published more than 300 manuscripts and has been chief or principal investigator on 30 major international multicentre trials, including first-in-man trials of new drug-eluting stents. His work has focused on the development and clinical evaluation of devices for the treatment of coronary artery and structural heart disease, and he has been at the forefront of emerging percutaneous cardiac valve therapies. He was also the global principal investigator for the Boston Scientific Lotus Valve REPRISE research programme.
He comments: “Boston Scientific has demonstrated a commitment to delivering meaningful innovation and I look forward to joining the team to further develop the technology pipeline and deliver solutions for patients worldwide.”
Mike Mahoney, chairman and chief executive officer, Boston Scientific, says: “Ian is one of the world’s leading cardiac device clinical investigators and he has been an advisor to Boston Scientific for many years. His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role. We are delighted that he will be joining our team.”
Keith Dawkins has announced his intention to retire from the company in January 2017. ”We thank Keith for his many contributions to Boston Scientific during the last nine years. His deep clinical, medical and strategic expertise and advocacy for the patient will have lasting influence within our company,” says Mahoney.
